Pilot clinical trial of parenteral lorazepam (Temesta�) in anxiety states

Bobon, J; Bourdouxhe, S; Breulet, M; Parent, Mike C.; Bobon, D

doi:10.1007/bf00437516

Cited by 11 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…De Paula (1977) found that the average time to achieve maximal anti-anxiety effect after intravenous administration was about 26 min for both diazepam (10 mg) and lorazepam (3 mg). Bobon et al (1973) reported that psychological and physiological manifestations of anxiety were modified within 5-10 min after intravenous administration of lorazepam (5 mg) while Walker et al (1979) observed a termination of seizures in status epilepticus within minutes following the intravenous injection of lorazepam (4-8 mg). Greenblatt et al (1977) showed that an acute antianxiety effect was evident within 5-10 min after intravenous injection of chlordiazepoxide (25 mg); this effect was maximal between 15 and 60 min and then abated rapidly.…”

Section: Discussionmentioning

confidence: 99%

Rate of entrance of benzodiazepines into the brain determined by eye movement recording.

Tedeschi¹,

Smith²,

Dhillon³

et al. 1983

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Peak saccadic velocity of horizontal eye movements, saccade duration at 30 degrees of amplitude and saccade reaction time were measured in six drug free male subjects. 2 In two separate experiments, intravenous doses of diazepam (5 mg), lorazepam (2 mg), chlordiazepoxide (25 mg) and placebo were given, and eye movement recordings were made before and at frequent intervals after drug administration. 3 All the benzodiazepines produced a significant impairment of peak saccadic velocity and saccade duration. Only lorazepam significantly affected saccade reaction time. 4 Time to achieve maximum effect was 10 min after diazepam, 29 min after lorazepam and 42 min after chlordiazepoxide.

show abstract

Section: Discussionmentioning

confidence: 99%

Rate of entrance of benzodiazepines into the brain determined by eye movement recording.

Tedeschi¹,

Smith²,

Dhillon³

et al. 1983

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Therefore, lorazepam appears to be suitable for parenteral use in acute anxiety. Placebo-controlled studies [Bobon et al, 1973;Breulet et al, 1974] found that intramuscular lorazepam was significantly su perior to placebo and that local irritation at the injection site was minimal. In an open clinical trial [Singh and Saxena, 1974], the therapeutic efficacy of three different dosages of intramuscular lorazepam was compared over a period of 8 h in 10 anxiety neurotic patients.…”

Section: Introductionmentioning

confidence: 99%

Intramuscular Lorazepam

Ananth¹,

N²

1983

Neuropsychobiology

View full text Add to dashboard Cite

In this double-blind, placebo-controlled study, 24 anxiety neurotic patients were randomly assigned equally into the intramuscular placebo, lorazepam or diazepam groups. The results indicated that lorazepam was as effective as diazepam in overall efficacy and was superior to diazepam in certain cluster scores including the Obsessive Compulsive Phobic Cluser of the Wittenborn Psychiatric Rating Scale.

show abstract

Clinical Pharmacokinetics of Lorazepam. III. Intravenous Injection. Preliminary Results

Greenblatt

Comer

Elliott

et al. 1977

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Four healthy male volunteers received 5 mg lorazepam as a single intravenous injection. Concentrations of lorazepam and its glucuronide metabolite were determined in multiple venous blood samples drawn during the 48 hours after dosing and in all urine collected during 96 hours after the dose. Mean pharmacokinetic parameters for lorazepam were: apparent elimination half-life, 13.2 hours; volume of distribution, 0.84 liter/kg; total clearance, 55.3 ml/min. Lorazepam glucuronide, the major metabolic product of lorazepam, promptly appeared in blood, reached peak levels within 6 hours of the dose, then declined in parallel with the parent compound. A mean of 69 per cent of the dose was recovered in urine as lorazepam glucuronide.

show abstract

Pilot clinical trial of parenteral lorazepam (Temesta�) in anxiety states

Cited by 11 publications

References 1 publication

Rate of entrance of benzodiazepines into the brain determined by eye movement recording.

Rate of entrance of benzodiazepines into the brain determined by eye movement recording.

Intramuscular Lorazepam

Clinical Pharmacokinetics of Lorazepam. III. Intravenous Injection. Preliminary Results

Contact Info

Product

Resources

About